We are a clinical-stage biopharmaceutical company with a unique approach to developing drugs for chronic inflammatory diseases, focusing on enhancing the epithelium.
EpiEndo Pharmaceuticals is founded on the hypothesis that acute exacerbations of chronic airway diseases (CADs) are primarily triggered by insults to the epithelial barrier of the airways. As a result, EpiEndo Pharmaceuticals aims to expand the therapeutic and diagnostic approaches for CADs beyond bronchoconstriction and inflammation.
Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs. Damage of this barrier is implicated in several chronic inflammatory conditions, including COPD and other lung diseases. By enhancing the epithelium and reducing inflammation, our lead compound, EP395, aims to slow disease progression.
COPD is the third largest cause of death globally, causing irreversible airflow obstruction. EP395, an oral barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients.
Our new class of oral drugs, known as Barriolides™, have the potential to be first-in-class therapies for respiratory diseases and beyond.
We have a unique approach to developing drugs for chronic inflammatory diseases, based on over 20 years of research into macrolides and their effects on the lung epithelium. The central focus of our pathophysiological models is on the acute immune response of the bronchial epithelial barrier, emphasising its breakdown, maladaptation, and dysfunction caused by persistent or overwhelming injury to the airway's mucosal lining.
This shift in perspective establishes a new theoretical basis for understanding, diagnosing, and treating CADs as epithelial diseases, rather than considering them solely as inflammatory diseases.
We are committed to sustainability and to minimizing our environmental impact and we are working towards formalizing our ESG policies. We measure ourselves against the United Nations Sustainable Development Goals and have implemented internal goals and policies that align with these goals.
EpiEndo aims to improve the quality of life of people with chronic diseases caused by epithelial dysfunction.
EpiEndo is committed to having an inclusive work culture with a healthy balance between work and private life.
EpiEndo, through its collaborative way of working, will continue to innovate and expand the life-science industry in Iceland.
EpiEndo works towards responsible consumption and production internally and externally.
At EpiEndo, we are dedicated to conducting our business with integrity and upholding the highest ethical standards. Our code of conduct sets the standard for our employees, partners, and suppliers, and outlines our commitment to ethical behavior, compliance with laws and regulations, and respect for the rights and dignity of all individuals. Our code of conduct reflects our values and our commitment to conducting business with the highest level of professionalism and ethical standards.